Regeneron begins phase III trial of COVID-19 treatment in U.K.

By The Science Advisory Board staff writers

September 14, 2020 -- Regeneron Pharmaceuticals and the University of Oxford have commenced a phase III clinical trial of potential treatments for COVID-19.

The Recovery open-label study is one of the largest COVID-19 trials in the world, according to Regeneron. It will compare the effectiveness of Regeneron's REGN-COV2 antibody therapy to the standard of care in patients hospitalized with COVID-19.

REGN-COV2 is also being evaluated in two other phase II and phase III trials to treat COVID-19 and prevent COVID-19 transmission among household members, according to Regeneron.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?